In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Previews (09/2009)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Looking Forward to Pharma's Decade of Predictive Efficacy," features profiles of Champions Biotechnology, Cytox, Immuneering and Rhenovia. Plus these Start-Ups Across Health Care: Freedom Meditech, MedShape Solutions, Molteni Therapeutics and TARIS Biomedical.

You may also be interested in...



Champions Biotechnology Inc.

Champions Biotechnology Inc.'s preclinical screening technology uses xenografts that it creates by implanting primary human cancer tumors into immune-deficient mice. The tumor cells are never passaged in cell tissue culture and therefore maintain the fundamental genotypic features of the original cancer because the risk of mutations through successive generations in culture is eliminated. The company has signed preclinical screening deals with a number of partners and it's also building its own therapeutic pipeline.

TARIS Biomedical Inc.

"Treat diseases locally" is a mantra espoused by a growing number of companies but few as yet have actually mustered the means to do so. TARIS Biomedical believes it has what it takes to become a pioneer of minimally invasive drug delivery devices. Its first product offering will be a pretzel-shaped device the size of a paper clip that will release medication inside the bladder, initially as a treatment for interstitial cystitis.

Rhenovia Pharma SAS

Rhenovia Pharma SAS believes it can help companies looking to improve existing Alzheimer's disease therapies by using computational models of the brain to identify chemical combinations capable of positively impacting disease symptoms. The start-up aims to build a service-based business running its specialized "biosimulations" on compounds that other companies currently market, have in development or have previously rejected for lack of efficacy.

Related Content

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003366

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel